NASDAQ:HTBX - Heat Biologics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.13 -0.01 (-0.88 %)
(As of 04/23/2019 04:07 AM ET)
Previous Close$1.14
Today's Range$1.08 - $1.1464
52-Week Range$0.95 - $4.30
Volume120,491 shs
Average Volume592,683 shs
Market Capitalization$37.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.79 million
Book Value$0.93 per share

Profitability

Net Income$-15,730,000.00
Net Margins-271.55%

Miscellaneous

Employees30
Market Cap$37.39 million
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Shares of Heat Biologics reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

How were Heat Biologics' earnings last quarter?

Heat Biologics Inc (NASDAQ:HTBX) released its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The biopharmaceutical company earned $1.84 million during the quarter, compared to analysts' expectations of $1.50 million. Heat Biologics had a negative net margin of 271.55% and a negative return on equity of 73.37%. View Heat Biologics' Earnings History.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Heat Biologics.

What price target have analysts set for HTBX?

3 Wall Street analysts have issued 1 year target prices for Heat Biologics' stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Heat Biologics' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 652.2% from the stock's current price. View Analyst Price Targets for Heat Biologics.

What is the consensus analysts' recommendation for Heat Biologics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

Has Heat Biologics been receiving favorable news coverage?

News coverage about HTBX stock has been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Heat Biologics earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future.

Who are some of Heat Biologics' key competitors?

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Palatin Technologies (PTN), Alibaba Group (BABA), Opko Health (OPK), Juno Therapeutics (JUNO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Sophiris Bio (SPHS), Biopharmx (BPMX) and Gevo (GEVO).

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the folowing people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
  • Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
  • Ms. Ann A. Rosar, Consultant (Age 67)
  • Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board

Who are Heat Biologics' major shareholders?

Heat Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.29%). View Institutional Ownership Trends for Heat Biologics.

Which major investors are buying Heat Biologics stock?

HTBX stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Heat Biologics.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $1.13.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $37.39 million and generates $5.79 million in revenue each year. Heat Biologics employs 30 workers across the globe.

What is Heat Biologics' official website?

The official website for Heat Biologics is http://www.heatbio.com.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]


MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  444
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel